Peter D. Eisenberg - Concepedia

Author

Peter D. Eisenberg

Also Known As

P D Eisenberg, P Eisenberg, P. D. Eisenberg, P. Eisenberg, P.D. Eisenberg, Peter D Eisenberg, Peter D. Eisenberg, Peter David Eisenberg, Peter Eisenberg

103

Publications

8.1K

Citations

H-Index

Concepts

All Affiliations

Marin Endocrine Care and Research The Barbara Ann Karmanos Cancer Institute Pfizer (United States)Princess Margaret Cancer Centre Dana-Farber Cancer Institute

About

Peter D. Eisenberg is an author at Marin Endocrine Care and Research specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	27	1.9K
2	Health Sciences	11	11	875
3	Nursing	1	1	25
4	Public Health	1	1	65
5	Anesthesia	1	1	49

Peter D. Eisenberg

Publications

7.9K

Citations

H-Index

Page 1

	Year	Citations
Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial Christina A. Meyers, Jennifer A. Smith, Andrea Bezjak, Journal of Clinical Oncology	2003	585
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane Harold J. Burstein, Anthony Elias, Hope S. Rugo, Journal of Clinical Oncology	2008	483
Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy David Warr, Paul J. Hesketh, Richard J. Gralla, Journal of Clinical Oncology	2005	464
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Journal of Clinical Oncology	2012	455
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT<sub>3</sub> receptor antagonist Peter D. Eisenberg, Jazmin Figueroa‐Vadillo, Rosalio Zamora, Cancer	2003	404
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Michael J. Moore, John Hamm, Janet Dancey, Journal of Clinical Oncology	2003	396
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion Lee S. Rosen, David Gordon, William Dugan, Cancer	2003	333
Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings Lorenzo Cohen, Carl A. de Moor, Peter D. Eisenberg, Supportive Care in Cancer Quality Of LifeCancer EducationChemotherapy-induced NauseaMedicineCancer Management	2006	327
Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer Jean‐Yves Douillard, Paulo M. Hoff, Jamey Skillings, Journal of Clinical Oncology	2002	322

Page 1